Allergy Therapeutics Share Price (AGY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Allergy Therapeutics	LSE:AGY	London	Ordinary Share	GB00B02LCQ05	ORD 0.1P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	+0.00p	+0.00%	8.20p	419,622	14:16:23

Bid Price		Offer Price	High Price	Low Price	Open Price
8.00p		8.40p	8.30p	8.20p	8.20p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	68.35	-6.90	-1.27		52.8

Related Shares
AstraZeneca (AZN), GlaxoSmithKline (GSK), Venn Life (VENN), Port Erin (PEBI)

Allergy Therapeutics (AGY) Latest News (1)

Allergy Therapeutics News

Date	Time	Source	Headline
22/3/2019	08:39	ALNCF	Alliance News Flash Headline
18/3/2019	16:41	UKREG	Allergy Therapeutics PLC Second Price Monitoring Extn
18/3/2019	16:36	UKREG	Allergy Therapeutics PLC Price Monitoring Extension
18/3/2019	11:05	UKREG	Allergy Therapeutics PLC Second Price Monitoring Extn
18/3/2019	11:00	UKREG	Allergy Therapeutics PLC Price Monitoring Extension
18/3/2019	10:06	ALNC	Allergy Therapeutics Surprised As Vaccine Trial Fails Primary Endpoint
18/3/2019	09:05	UKREG	Allergy Therapeutics PLC Second Price Monitoring Extn
18/3/2019	09:00	UKREG	Allergy Therapeutics PLC Price Monitoring Extension
18/3/2019	07:01	UKREG	Allergy Therapeutics PLC Top Line Phase III results from B301 trial
06/3/2019	11:13	ALNC	Allergy Therapeutics Interim Profit Rises 67% On Higher Revenue

More Allergy Therapeutics News

Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Share Charts

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Intraday Allergy Therapeutics Chart

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date	Time	Title	Posts
22/3/2019	12:12	Allergy Therapeutics - AGY -	3,620
14/7/2016	20:04	Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)	1
16/12/2015	10:24	Allergy Therapeutics-Transforming Allergy Treatment	26
03/2/2012	13:58	Ready to ROCKET?	-
04/12/2005	12:00	AGY - Allergy Therapeutics	79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-03-22 16:29:25	8.35	2,923	243.92	O
2019-03-22 16:28:25	8.25	8,837	729.05	O
2019-03-22 16:26:58	8.35	9,586	799.95	O
2019-03-22 16:21:56	8.35	11,983	999.98	O
2019-03-22 16:18:08	8.35	6,160	514.05	O

View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

Date	Subject
22/3/2019 08:20	Allergy Therapeutics Daily Update: Allergy Therapeutics is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 8.20p. Allergy Therapeutics has a 4 week average price of 7.35p and a 12 week average price of 7.35p. The 1 year high share price is 29p while the 1 year low share price is currently 7.35p. There are currently 644,117,768 shares in issue and the average daily traded volume is 4,671,024 shares. The market capitalisation of Allergy Therapeutics is £52,817,656.98. Read Full Thread Reply
22/3/2019 12:12	eltorres70: How can anyone still believe in this company when all they do is fail and put smoke in people’s eyes, they’ve been doing this for the past 10 years and that’s a fact. And the regression of their share price is hard proof. Finncap is the same source that was suggesting 40p before people lost loads of money. Birch trial proved ineffectiveness of all their current injectible treatments. They have no viable plans for the future, competitors are already light years ahead. Only a naive speculator can still believe the tales they’re telling. Read Full Thread Follow Reply
26/2/2019 14:00	beccasan: I find it hard to firmly believe in AGY as much as you do Jimmy. After all the discussions on this board over the last few months, I am just not that confident anymore. We shall see how the birch trials turn out, but at the moment the market seems to be weak and this company is looking particularly weak against competitors, as it looks like all AGY projects are quite outdated while other similar companies are moving at a faster pace. We shall see once they start putting out news with results, but I currently wouldn't get my hopes too high up, and given the present share price I assume big investors are just as sceptic. Read Full Thread Follow Reply
28/11/2018 17:52	beccasan: I used to think like you but now I am not that sure anymore. This looks like a solid downwards trend, as share price is dropping at last 5% every day! In case bad news awaits in 2019 for the trials, things can get real bad real quick, I am personally very worried, very risky moment Read Full Thread Follow Reply
23/10/2018 15:21	mobox1: Current AGY website states these companies having major holdings: CFR International SPA & Associated Holding 240,584,571 37.82% Southern Fox Investments 127,238,783 22.69% Odey Assest Management 43,747,523 6.88% Black Rock Investment Management 30,368,413 4.79% Invesco 28,618,373 4.50& Black Rock still have someway to go if current % accurate & they want to offload everything. Annoying that they are selling at a time of little news and poor liquidity which knackers the share price. Can't have made them much profit. Read Full Thread Follow Reply
22/5/2018 17:51	gersemi: Today - IC Tip Update: Buy at 27p Megan Boxall The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose. If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses keep widening, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments. IC View Even with the 9 per cent one-day share price hike which followed these results, Allergy’s share price is still down in the last 12 months. We don’t think that’s a fair reflection of the clinical progress that has been made in that time. Buy at 27p. Last IC View: Buy, 26p, 7 Mar 2018 Read Full Thread Follow Reply
22/11/2017 09:49	jpuff: Why the collapse in the share price? Read Full Thread Follow Reply
21/9/2017 17:32	gersemi: Tipped in the IC Tip Update: Buy at 32.3p Tip style - GROWTH Risk rating -HIGH Timescale - LONG TERM Our previous tip -We said BUY at 19.8p on 21 Jul 2016 Tip performance to date - +63% By Megan Boxall The US allergy pharmaceuticals market has the potential to be very lucrative. Roughly 18m Americans sniff and itch their way through the hay fever season each year and, at present, treatment options are limited. But it is also a notoriously tricky sector to navigate. Allergy Therapeutics (AGY) is proof of that, gaining the go-ahead for the phase II clinical trial of its new grass allergy medicine – Pollinex Quattro (PQ) – after 10 years. In 2007, Allergy’s final trial into the efficacy of PQ was put on hold after a participant reported numbness and weakening, which regulators couldn’t be sure had nothing to do with the treatment. That hold was only lifted in 2011, and since then the group has failed to show US regulators an acceptable dosage of the drug. But with demand for PQ so strong, Allergy has been given the go-ahead to try again. The newest dosing study will begin imminently, according to management, and is expected to release results by the second half of 2018. If approved, PQ will be the first injectable allergy treatment available in the US. But as well as sidestepping tight regulation, Allergy Therapeutics must hurdle another demon of the allergy drugs market: the placebo effect. In 1999 a food allergy vaccine made by Peptide Therapeutics successfully helped 75 per cent of patients on a clinical trial tolerate more of the food they were allergic to. Unfortunately, a similar number of patients on the placebo treatment responded the same way, meaning the trial was deemed a failure. It was a similar story at Circassia (CIR) last year when its cat allergy treatment failed to show any significant benefits above the placebo drug, which had improved symptoms by 59 per cent. Many academic studies have found this high placebo effect to be common in allergy drugs trials, but no-one can fully explain why. Allergy Therapeutics should be more immune to placebo effect than its peers. PQ has already successfully improved the symptoms of more than 250,000 patients and is marketed in seven countries. Moreover, the trial has not been designed using the self-report measures that have caused problems for many allergy studies; instead patients’ eyes will be observed for signs of improvement before and after treatment. IC View Investors have been slow to forgive Allergy Therapeutics for its US misfortunes. The share price has gained good momentum in the past few months, but at 32p it is still far from its 2006 highs. There are factors to be wary of that are outside of the company’s control, such as tight US allergy regulation, but demand for PQ is clearly high. If Allergy can crack the tough US regulatory environment, the financial rewards could be big. Buy. Last IC View: Buy, 25p, 03 Apr 2017 - Read Full Thread Follow Reply
01/2/2017 19:52	jimmyloser: Upside still to be seen according to analyst. Allergy Therapeutics (LON:AGY) will take its Polyvac vaccine for peanut allergy into a phase I clinical trial after it delivered positive pre-clinical results. The findings showed a single dose of the company's unique adjuvant when combined with recombinant peanut allergen successfully protected against the serious allergic reaction anaphylaxis. The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments. “Hundreds of patients die each year in the United States as a result of food allergies (mainly peanut) and we are committed to saving these lives,” said Allergy Therapeutics chief executive Manuel Llobet. “This peanut vaccine programme complements our current range of marketed ultra-short course vaccines in terms of safety, efficacy and improved patient convenience." The shares rose 6% in afternoon trade to 27.5p. However the company’s broker, finnCap, thinks they have further to go. Analyst Mark Brewer points out Allergy trades on an enterprise value/sales multiple of just two-times when its peers are on 3.2-times. He reckons the shares are worth 43p each with “substantial further upside” as its hay fever drug Pollinex Quattro progresses through the development phases. “We currently attribute no value to Polyvac Peanut and will re-assess as it moves into human studies,” said Brewer. ---adds broker comment, share price--- Read Full Thread Follow Reply
06/1/2017 16:18	audigger: An encouraging start to the New Year..... Allergy Therapeutics plc 92.8% Potential Upside Indicated by finnCap Allergy Therapeutics plc with EPIC/TICKER LON:AGY had its stock rating noted as ‘Initiates/Starts’ with the recommendation being set at ‘BUY’ this morning by analysts at finnCap. Allergy Therapeutics plc are listed in the Health Care sector within AIM. finnCap have set their target price at 40 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 92.8% from the opening price of 20.75 GBX. Over the last 30 and 90 trading days the company share price has increased 0.67 points and increased 0.57 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 21.27 GBX and the 200 Day Moving Average price is recorded at GBX. The 1 year high share price is 30 GBX while the year low stock price is currently 17.25 GBX. There are currently 598,491,373 shares in issue with the average daily volume traded being 86,871. Market capitalisation for LON:AGY is £122,989,973 GBP. Read Full Thread Follow Reply
29/9/2016 17:14	jimmyloser: From elsewhere on the web Allergy Therapeutics plc 198.6% Potential Upside Indicated by Panmure Gordon by: Amilia Stone 26th September 2016 Allergy Therapeutics plc using EPIC/TICKER code LON:AGY has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Allergy Therapeutics plc are listed in the Health Care sector within AIM. Panmure Gordon have set their target price at 53 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 198.6% from today’s opening price of 17.75 GBX. Over the last 30 and 90 trading days the company share price has decreased 1.35 points and decreased 1.3 points respectively. Allergy Therapeutics plc LON:AGY has a 50 day moving average of 19.03 GBX and a 200 day moving average of GBX. The 1 year high for the stock price is 34.82 GBX while the 52 week low for the stock is 17.29 GBX. There are currently 601,432,778 shares in issue with the average daily volume traded being 252,540. Market capitalisation for LON:AGY is £106,934,752 GBP. Allergy Therapeutics plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company’s business segments are Central Europe, Southern Europe, the United Kingdom and Rest of World. Read Full Thread Follow Reply

Allergy Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

LSE

AGY

Allergy Th..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190323 08:16:00